FPMI: AI 评分 51/100 — AI 分析 (4月 2026)

FluoroPharma Medical, Inc. is a biopharmaceutical company focused on developing molecular imaging pharmaceuticals for cardiology. Their lead product candidates target coronary artery disease (CAD) diagnosis and management.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

FluoroPharma Medical, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of molecular imaging pharmaceuticals, primarily targeting cardiology applications such as coronary artery disease (CAD) diagnosis. Their pipeline includes BFPET and CardioPET, imaging agents designed to improve CAD assessment and management, positioning them within the niche molecular imaging market.

FPMI是做什么的？

Founded in 2003 and headquartered in Montclair, New Jersey, FluoroPharma Medical, Inc. is a biopharmaceutical company focused on the development of molecular imaging pharmaceuticals, with a particular emphasis on cardiology. The company's mission is to improve the diagnosis and management of cardiovascular diseases through advanced imaging technologies. Its lead product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial for stress-testing in patients with suspected or proven coronary artery disease (CAD), and CardioPET, a molecular imaging agent currently in Phase IIa clinical trials to assess myocardial blood flow and metabolism in CAD patients. FluoroPharma operates through license agreements with institutions like Massachusetts General Hospital and Sinotau USA, and has established clinical research agreements with Pharmaceutical Product Development, LLC, and Cardiovascular Imaging Technologies. The company's focus on molecular imaging in cardiology aims to provide clinicians with enhanced diagnostic tools for better patient outcomes. Despite its small size, with only 4 employees, FluoroPharma is actively pursuing clinical development and partnerships to advance its pipeline.

FPMI的投资论点是什么？

FluoroPharma Medical, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful development and commercialization of its molecular imaging agents, BFPET and CardioPET, targeting the diagnosis of coronary artery disease (CAD). Positive Phase IIa trial results for CardioPET could serve as a significant catalyst, potentially attracting strategic partnerships or acquisition interest. However, the company's limited financial resources, small team, and reliance on clinical trial outcomes introduce substantial risks. The negative beta of -69.72 suggests an inverse correlation with the market, which may be misleading given the company's stage and specific risks. Investors should carefully weigh the potential upside against the inherent uncertainties of biopharmaceutical development and the company's OTC market listing.

FPMI在哪个行业运营？

FluoroPharma Medical, Inc. operates within the biotechnology industry, specifically targeting the molecular imaging segment within cardiology. The market for cardiovascular imaging is growing, driven by the increasing prevalence of heart disease and the demand for more accurate diagnostic tools. Competition includes established players in medical imaging and other biotechnology companies developing novel diagnostic agents. FluoroPharma's success depends on its ability to differentiate its products through superior efficacy, safety, and cost-effectiveness. The company's focus on CAD diagnosis positions it within a critical area of unmet medical need.

Biotechnology

Healthcare

FPMI有哪些增长机遇？

Successful Completion of CardioPET Phase IIa Trial: Positive results from the ongoing Phase IIa clinical trial for CardioPET could significantly enhance its market value. This trial assesses myocardial blood flow and metabolism in CAD patients. Success would validate the technology and attract potential partnerships or funding for further development and larger Phase III trials, potentially leading to commercialization within 3-5 years. The market for advanced cardiac imaging is projected to reach billions of dollars, offering substantial revenue potential.
Strategic Partnerships for BFPET Commercialization: FluoroPharma could pursue strategic partnerships with larger pharmaceutical or medical device companies to commercialize BFPET, which has completed Phase I trials. Partnering would provide access to resources and expertise for regulatory approval and market launch. The market for stress-testing agents is substantial, and a successful partnership could generate significant revenue streams within 2-3 years.
Expansion into New Cardiovascular Applications: FluoroPharma can leverage its molecular imaging technology to expand into new cardiovascular applications beyond CAD diagnosis. This could include imaging agents for heart failure, stroke, or peripheral artery disease. Expanding the product pipeline would diversify revenue streams and reduce reliance on single product success. This expansion could begin within the next 3-5 years, requiring further research and development.
Geographic Expansion into International Markets: FluoroPharma could explore opportunities to expand its market reach into international markets, particularly Europe and Asia, where there is a growing demand for advanced cardiac imaging technologies. This expansion would require regulatory approvals and strategic partnerships with local distributors. International expansion could begin within 3-5 years, contingent on successful clinical trials and regulatory pathways.
Development of Companion Diagnostics: FluoroPharma can develop companion diagnostics to identify patients who are most likely to benefit from specific cardiovascular therapies. This would enhance the value proposition of its imaging agents and create opportunities for personalized medicine. Companion diagnostics could improve treatment outcomes and reduce healthcare costs. Development could begin within 2-3 years, requiring collaboration with pharmaceutical companies.

FluoroPharma Medical, Inc. focuses on molecular imaging pharmaceuticals for cardiology, specifically coronary artery disease (CAD).
BFPET, a key product candidate, has completed Phase I clinical trials for stress-testing in CAD patients.
CardioPET, another product candidate, is in Phase IIa clinical trials to assess myocardial blood flow and metabolism in CAD patients.
The company has license agreements with Massachusetts General Hospital and Sinotau USA.
FluoroPharma Medical, Inc. has a market capitalization of $0.00B, indicating its small size and early stage of development.

FPMI提供哪些产品和服务？

Develop molecular imaging pharmaceuticals.
Focus on cardiology applications.
Create imaging agents for coronary artery disease (CAD) diagnosis.
Conduct clinical trials to assess the safety and efficacy of their products.
Seek regulatory approval for their products from the FDA.
Commercialize their products through partnerships or direct sales.

FPMI如何赚钱？

Develop and patent novel molecular imaging agents.
Conduct clinical trials to demonstrate safety and efficacy.
License or partner with larger pharmaceutical companies for commercialization.
Generate revenue through licensing fees, milestone payments, and royalties.

Cardiologists
Hospitals and imaging centers
Patients with suspected or proven coronary artery disease (CAD)

Proprietary molecular imaging technology
Patent protection for key product candidates
Clinical data supporting the efficacy of their products
Established relationships with key opinion leaders in cardiology

什么因素可能推动FPMI股价上涨？

Upcoming: CardioPET Phase IIa trial results expected in late 2026, which could validate the technology and attract partnerships.
Ongoing: Continued clinical development of BFPET for stress-testing in CAD patients.
Ongoing: Potential for strategic partnerships with larger pharmaceutical or medical device companies.
Upcoming: Possible expansion into new cardiovascular applications within the next 3-5 years.
Ongoing: Exploration of geographic expansion into international markets.

FPMI的主要风险是什么？

Potential: Clinical trial failures for BFPET or CardioPET could significantly impact the company's value.
Ongoing: Limited financial resources and small team pose challenges to product development and commercialization.
Ongoing: Competition from established players in the medical imaging market.
Potential: Regulatory hurdles and delays in obtaining FDA approval.
Ongoing: OTC market listing increases the risk of price volatility and manipulation.

FPMI的核心优势是什么？

Proprietary molecular imaging technology
Focus on a specific therapeutic area (cardiology)
Clinical data supporting the efficacy of their products
Experienced management team

FPMI的劣势是什么？

Limited financial resources
Small team
Reliance on clinical trial outcomes
OTC market listing

FPMI有哪些机遇？

Strategic partnerships with larger pharmaceutical companies
Expansion into new cardiovascular applications
Geographic expansion into international markets
Development of companion diagnostics

FPMI面临哪些威胁？

Competition from established players in medical imaging
Regulatory hurdles
Clinical trial failures
Economic downturn

FPMI的竞争对手是谁？

Anthera Pharmaceuticals, Inc. — Focuses on different therapeutic areas. — (ANTH)
Bio-Path Holdings, Inc. — Develops different drug delivery technologies. — (BBAL)
Comera Life Sciences Holdings, Inc. — Focuses on subcutaneous biologics. — (CMRA)
Evelo Biosciences, Inc. — Develops microbial medicines. — (EVLO)
Natural Immunogenics Corp. — Focuses on silver-based health products. — (NTII)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Edward L. Lyons Jr.
Headquarters: Montclair, US
Employees: 4
Founded: 2011

AI Insight

AI analysis pending for FPMI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does FluoroPharma Medical, Inc. do?

FluoroPharma Medical, Inc. is a biopharmaceutical company focused on developing and commercializing molecular imaging pharmaceuticals for cardiology, particularly for the diagnosis and management of coronary artery disease (CAD). Their lead product candidates, BFPET and CardioPET, are designed to improve the accuracy and efficiency of cardiac imaging, providing clinicians with better tools for assessing myocardial blood flow and metabolism. The company aims to address the unmet needs in cardiovascular diagnostics through innovative imaging technologies.

What do analysts say about FPMI stock?

As of March 18, 2026, there is no readily available analyst coverage for FluoroPharma Medical, Inc. This lack of coverage is typical for companies trading on the OTC market with a small market capitalization. Investors should conduct their own thorough due diligence and consider the inherent risks associated with investing in thinly traded, early-stage biopharmaceutical companies. Key valuation metrics are not widely available, and growth considerations are primarily tied to the successful development and commercialization of their product pipeline.

What are the main risks for FPMI?

FluoroPharma Medical, Inc. faces several significant risks inherent to its business and market position. As a biopharmaceutical company, clinical trial failures for BFPET or CardioPET represent a major risk, potentially halting product development and eroding investor confidence. The company's limited financial resources and small team pose challenges to advancing its pipeline and competing with larger, more established players. Additionally, the OTC market listing increases the risk of price volatility and manipulation, making it crucial for investors to exercise caution.